Current Trends in the Management of Bladder Cancer

被引:2
作者
Patel, Amit R. [1 ]
Campbell, Steven C. [1 ]
机构
[1] Cleveland Clin, Glickman Urol & Kidney Inst, Sect Urol Oncol, Cleveland, OH 44195 USA
关键词
RESTAGING TRANSURETHRAL RESECTION; LONG-TERM-SURVIVAL; RADICAL CYSTECTOMY; NEOADJUVANT CHEMOTHERAPY; RISK; IMPACT; STAGE; LYMPHADENECTOMY; INSTILLATION; METAANALYSIS;
D O I
10.1097/WON.0b013e3181aaf1e7
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
This article provides a review of bladder cancer etiology, diagnosis, and management for WOC nurses. Bladder cancer incidence continues to rise yearly in the United States, and patients with bladder cancer comprise some of the most challenging cases in urologic oncology. Nurses are involved with all aspects of the processes of care for the patient with bladder cancer, from initial diagnosis and treatment to post-surgical care and follow-up. For nonmuscle invasive bladder cancer, treatment includes transurethral resection followed by intravesical chemotherapy or immunotherapy to prevent recurrence or progression. Radical cystectomy along with chemotherapy protocols provides a survival advantage for muscle invasive bladder cancer, although the timing of chemotherapy remains controversial. Numerous factors are considered when determining the type of urinary diversion used at the time of radical cystectomy, but patient, family, surgeon, and nursing input are essential for preserving an optimal health-related quality of life and reducing morbidity. Patients with metastatic bladder cancer are generally treated with a cisplatin-based chemotherapy but continue to have a poor prognosis. Newer therapies involving novel molecular-targeted agents provide hope for the future for patients with metastatic disease.
引用
收藏
页码:413 / 421
页数:9
相关论文
共 37 条
[1]  
[Anonymous], J UROL
[2]   Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy [J].
Bajorin, DF ;
Dodd, PM ;
Mazumdar, M ;
Fazzari, M ;
McCaffrey, JA ;
Scher, HI ;
Herr, H ;
Higgins, G ;
Boyle, MG .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3173-3181
[3]  
Campbell MF., 2007, CAMPBELL WALSH UROLO
[4]   Impact of a second transurethral resection on the staging of T1 bladder cancer [J].
Dalbagni, G ;
Herr, HW ;
Reuter, VE .
UROLOGY, 2002, 60 (05) :822-824
[5]   Cystectomy for bladder cancer: A contemporary series [J].
Dalbagni, G ;
Genega, E ;
Hashibe, M ;
Zhang, ZF ;
Russo, P ;
Herr, H ;
Reuter, V .
JOURNAL OF UROLOGY, 2001, 165 (04) :1111-1116
[6]   Systemic chemotherapy for advanced bladder cancer: Update and controversies [J].
Garcia, Jorge A. ;
Dreicer, Robert .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (35) :5545-5551
[7]  
Grossfeld GD, 2001, AM FAM PHYSICIAN, V63, P1145
[8]  
Grossman HB, 2006, UROLOGY, V67, P45
[9]   Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [J].
Grossman, HB ;
Natale, RB ;
Tangen, CM ;
Speights, VO ;
Vogelzang, NJ ;
Trump, DL ;
White, RWD ;
Sarosdy, MF ;
Wood, DP ;
Raghavan, D ;
Crawford, ED .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (09) :859-866
[10]   Quality of life in patients with bladder carcinoma after cystectomy: First results of a prospective study [J].
Hardt, J ;
Filipas, D ;
Hohenfellner, R ;
Egle, UT .
QUALITY OF LIFE RESEARCH, 2000, 9 (01) :1-12